PRMA Insights: The Roadmap to Pricing and Reimbursement Success

Scope of the psoriasis report

Comprehensive secondary research, experienced based insight and validation by payers and Key Opinion Leaders (KOLs) across markets underpins prmainsights™: The Roadmap to Pricing and Reimbursement Success in Psoriasis:

Reporting of the regulatory nominations and key supporting data for the following biologics:

Amevive

Enbrel

Remicade

Stelara

Humira

 

The current pricing and reimbursement landscape for psoriasis in the Top 7 major pharmaceutical markets:

US

UK

France

Germany

Spain

Italy

Japan

 

Reviews of psoriasis clinical guidelines as published by:

AAD	EDF	BAD	HAS	BVDD	GUF
Spanish Psoriasis Working Group

 

A comprehensive review and assessment of all pricing and reimbursement and HTA decisions for biologics for the treatment of moderate to severe psoriasis.

The assessments of over 25 HTA and pricing and reimbursement decisions recently made in psoriasis by the following bodies:

AIFA	CEPS	CMS	DGFPS	G-BA	InEK	IQWiG
MHLW	NICE	SMC	TC	UVEF

Find out more about the psoriasis report:

The report delivers         Scope of the report        Authors of the report